Reclast (zoledronic acid or zoledronate) is an infusion to treat osteoporosis. It's typically covered by Original Medicare (parts A and B).

Discover the four key trends and innovations driving infusion therapy for chronic diseases as we head into 2025. Stay informed and up-to-date on the latest advancements in healthcare.

In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line ...